Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Karyopharm Therapeutics Inc. (KPTI) had Debt to Equity Ratio of -0.87 for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$30.02M |
|
$-23.46M |
|
$1.30M |
|
$28.71M |
|
$63.27M |
|
$-33.26M |
|
$9.83M |
|
$-23.43M |
|
$-23.43M |
|
$-23.46M |
|
$-23.46M |
|
$-23.46M |
|
$-23.46M |
|
$-33.26M |
|
$-30.84M |
|
8.47M |
|
8.47M |
|
$-2.77 |
|
$-2.77 |
|
| Balance Sheet Financials | |
$120.24M |
|
$0.32M |
|
$7.47M |
|
$127.71M |
|
$90.37M |
|
$154.83M |
|
$243.22M |
|
$333.60M |
|
$-205.88M |
|
$-205.88M |
|
$-205.88M |
|
8.57M |
|
| Cash Flow Statement Financials | |
$-38.98M |
|
$15.29M |
|
-- |
|
$62.81M |
|
$39.12M |
|
$-23.69M |
|
$3.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.33 |
|
-- |
|
-- |
|
-3.03 |
|
|
Debt to Equity Ratio |
-0.87 |
95.67% |
|
-110.80% |
|
-110.80% |
|
-- |
|
-78.05% |
|
-78.17% |
|
$-38.98M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
0.27 |
|
0.85 |
|
105.68 |
|
11.40% |
|
11.40% |
|
-18.37% |
|
45.96% |
|
$-24.03 |
|
$-4.60 |
|
$-4.60 |
|